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Background-—Animal study results point to oxidative stress as a key mechanism triggering postoperative atrial ﬁbrillation (PoAF),
yet the extent to which speciﬁc biomarkers of oxidative stress might relate to PoAF risk in humans remains speculative.
Methods and Results-—We assessed the association of validated, fatty acid–derived oxidative stress biomarkers (F2-isoprostanes,
isofurans, and F3-isoprostanes) in plasma and urine, with incident PoAF among 551 cardiac surgery patients. Biomarkers were
measured at enrollment, the end of surgery, and postoperative day 2. PoAF lasting ≥30 seconds was conﬁrmed with rhythm strip
or electrocardiography and centrally adjudicated. Outcomes were assessed until hospital discharge or postoperative day 10,
whichever occurred ﬁrst. Urine level of each oxidative stress biomarker rose at the end of surgery (2- to 3-fold over baseline,
P<0.001) and subsequently declined to concentrations comparable to baseline by postoperative day 2. In contrast, plasma
concentrations remained relatively stable throughout the perioperative course. Urine F2-isoprostanes and isofurans at the end of
surgery were 20% and 50% higher in subjects who developed PoAF (P≤0.009). While baseline biomarker levels did not associate
signiﬁcantly with PoAF, end of surgery and postoperative day 2 isoprostanes and isofurans demonstrated relatively linear
associations with PoAF. For example, the end of surgery extreme quartile multivariate adjusted OR (95% CI) for urine isofurans and
F3-isoprostanes were 1.95 (1.05 to 3.62; P for trend=0.01) and 2.10 (1.04 to 2.25, P for trend=0.04), respectively. The
associations of biomarkers with PoAF varied little by demographics, surgery type, and medication use (P≥0.29 for each).
Conclusions-—These novel results add to accumulating evidence supporting the likely key pathogenic role of elevated oxidative
stress in PoAF.
Clinical Trial Registration-—URL: Clinicaltrials.gov Unique identiﬁer: NCT00970489. ( J Am Heart Assoc. 2015;4:e001886 doi:
10.1161/JAHA.115.001886)
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P ostoperative atrial ﬁbrillation (PoAF) commonly compli-cates cardiac surgery. PoAF increases the risk of
thromboembolic events, prolongs hospital care, increases
healthcare costs, and elevates long-term mortality.1 Current
frontline therapy such as b-blockers and amiodarone only
partly prevent PoAF, likely reﬂecting the complex, multifactorial
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pathogenesis of PoAF.2 Improved understanding of the precise
molecular and physiologic mechanisms contributing to PoAF
could promote the development of novel targeted
interventions.
Experimental evidence suggests oxidative stress can con-
tribute to the pathogenesis of PoAF.2 Oxidative stress occurs
when excess production of reactive oxygen species (ROS)
overwhelms endogenous antioxidant defenses, resulting in
tissue injury. In animal studies, oxidative stress contributed to
cardiac myocyte dysfunction, electrical and structural remod-
eling, and the development of AF.3–5 Furthermore, oxidative
stress could potentiate PoAF via activation of stress signaling
pathways and inﬂammatory responses, which in turn amplify
tissue injury.6,7 Evidence supporting the relationship between
oxidative stress and PoAF in humans, however, remains limited.
Studies based on analyses of human atrial tissues collected
during cardiac surgery suggest a pathogenic role of oxidative
stress and, in particular, identiﬁed elevated atrial nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase activity as
associated with PoAF.8,9 Conversely, measurements of circu-
lating oxidative stress biomarkers have yielded mixed ﬁnd-
ings,9–11 although such studies typically assessed oxidative
stress by using biomarkers with low sensitivity and speciﬁcity,
which could obscure potential associations.12 Furthermore,
although levels of oxidative stress vary throughout the
perioperative time course,13 there is a lack of comprehensive
evaluation of the relationship of oxidative stress with PoAF at
different cardiac surgery time points.
To investigate further the role of oxidative stress in PoAF,
we tested the hypothesis that plasma and urine levels of F2-
isoprostanes (F2-isoP), isofurans (IsoF), and F3-isoprostanes
(F3-IsoP) associate with incident PoAF in a subset of 551
subjects in the Omega-3 Fatty Acids for Prevention of Post-
Operative Atrial Fibrillation (OPERA) trial.14 F2-isoP, IsoF, and
F3-IsoP are highly sensitive and robust lipid oxidation
biomarkers derived from arachidonic acid (F2-isoP and IsoF)
and eicosapentaenoic acid (F3-IsoP).
15,16 Concentrations of
these biomarkers were measured at baseline (ie, at study
recruitment, representing baseline ambulatory levels of oxi-
dative stress), at the end of cardiac surgery (reﬂecting acute
changes in oxidative damage following ischemia–reperfusion),
and again at postoperative day 2 (to capture trends in
persistently elevated or oxidative stress or, conversely, return
to homeostasis).
Methods
Design and Population
This investigation was designed as an ancillary study of the
OPERA trial, which was a randomized, placebo-controlled study
that found perioperative ﬁsh oil supplementation did not reduce
PoAF.14 Design of the OPERA study has been reported in detail
previously.17,18 In brief, the study enrolled 1516 patients from
28 medical centers undergoing cardiac surgery in 3 countries
(United States, Italy, and Argentina). The inclusion criteria were
broad: age ≥18 years, presence of sinus rhythm on the
screening electrocardiogram (ECG), and being scheduled for
cardiac surgery on the following day or later. Exclusions were
absence of sinus rhythm at screening, regular use of ﬁsh oil,
known intolerance or allergy to ﬁsh oil or olive oil (placebo),
unable or unwilling to provide informed consent, being currently
pregnant, or having an existing or a planned cardiac transplant
or use of ventricular assist device. All participants provided
written informed consent, and the study was approved by the
human subjects committees of all participating institutions.
Seventeen study centers participated in this ancillary study.
Oxidative Stress Biomarkers
EDTA-anticoagulated fasting blood and spot urine samples
were collected from subjects with the use of standardized kits
and techniques at baseline, the end of cardiac surgery, and
postoperative day 2. Biologic samples were stored at 70°C
at each study center and subsequently transferred on dry ice
to a central sample bank for long-term storage at 80°C.
After completion of the OPERA study, oxidative stress
biomarkers were measured at the Eicosanoid Core Laboratory
at Vanderbilt University with the use of highly robust and
speciﬁc gas chromatography–mass spectrometry.19 Limits of
detection were 1, 5, and 10 pg/mL for F2-IsoP, F3-Iso, and
IsoF, respectively. Interassay coefﬁcient of variations were
≤15%. Levels of oxidative stress biomarkers in plasma are
reported in picograms per milliliter, whereas their levels in
urine are normalized to creatinine clearance and reported as
nanograms per milligrams of creatinine. We were unable to
quantify oxidative stress biomarkers in a small portion of
samples (≤2% for F2-IsoP and IsoF, ≤12% for F3-IsoP) due to
coeluting contaminants, and these samples were thus
excluded from the analyses. If the level of an oxidative stress
biomarker in a sample was less than the assay detection limit,
its value was imputed as half of the detection limit.
Covariates
Other potential risk factors for PoAF were assessed by using
standardized methods including demographics, lifestyle
behaviors, cardiovascular risk factors, anthropometric mea-
surements, medical and surgical history, comorbidities, med-
ication use (outpatient and inpatient), echocardiographic
evaluation, and laboratory measures. Additional data were
collected regarding surgical procedure and daily follow-up and
discharge information.
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Outcomes
A centralized events committee of cardiac electrophysiolo-
gists reviewed and adjudicated all suspected episodes of
PoAF, based on documentations including duration, clinical
information, and conﬁrmatory rhythm strip or 12-lead ECG.
The primary end point for this analysis is incident PoAF of
≥30 seconds’ duration, with outcomes assessed until hospital
discharge or postoperative day 10, whichever occurred ﬁrst.
Statistical Analysis
The interrelationships between individual oxidative stress
biomarkers were assessed at each time point by using
Spearman correlation coefﬁcients. Changes in biomarker level
between study time points were assessed with paired t test.
Oxidative stress biomarker concentrations were evaluated in
quartiles as indicator variables, and their associations with
incident PoAF were investigated by using multivariable-
adjusted logistic regression. Biomarkers were also examined
as continuous variables after log transformation because these
variables were right-skewed. Tests of linear trend were
conducted by assigning to participants the median value in
each quartile and assessing this as a single continuous
variable. We also examined possible nonlinear relationships
between circulating and urine biomarkers and risk of PoAF
nonparametrically by using restricted cubic splines, after
excluding participants with extreme values (<1st or >99th
percentile) to minimize the effects of outliers. To minimize
confounding, we adjusted for age, sex, country, body mass
index, prevalent hypertension, prevalent diabetes, prevalent
coronary heart disease, prevalent chronic renal failure,
prevalent heart failure, smoking, dyslipidemia, statin medica-
tion use, left ventricular ejection fraction, and logistic Euro-
score.20 Adjustment for treatment did not make a difference
and was not included in the ﬁnal model. Missing covariates
(<3%) were singly imputed by best-subset-regression with
demographic/risk variables. Results were similar excluding
those with missing covariate values. In sensitivity analyses, we
also assessed the association between changes in oxidative
stress biomarker concentrations from baseline to end of
surgery and PoAF.
Effect modiﬁcation were evaluated in stratiﬁed analyses for
several subgroups including age (<median, ≥median), sex,
country, body mass index (<median, ≥median), type of surgery
(valve surgery versus nonvalve surgery), smoking (current
versus ex-smokers and nonsmokers), aspirin use, and statin
use. For each subgroup, oxidative stress biomarkers were
assessed in stratum-speciﬁc quartiles as indicator variables.
The signiﬁcance of potential effect modiﬁcation was tested by
using the Wald test for a multiplicative interaction term
between the biomarker quartiles (evaluated as ordinal
variables) and the stratiﬁcation variable, with Bonferroni-
corrected a level to account for multiple comparisons. All P
values were 2-tailed (a=0.05), and analyses were performed
with Stata 13.1 (Stata Corp).
Results
The mean age of the participants was 63 years, and the
majority (72%) were men (Table). Subjects were enrolled in
the United States (57%), Italy (32%), and Argentina (11%). As
expected, there was a high prevalence of cardiometabolic
risk factors, including hypertension and dyslipidemia, and
nearly 50% of the subjects have a history of coronary heart
disease.
The levels of individual oxidative stress biomarkers and
their correlations are shown in the online supplemental data
(Table S1). While the concentrations of F2-IsoP and IsoF were
similar, they were an order of magnitude larger than F3-Iso in
both plasma and urine. Biomarkers measured in the same
compartment (plasma or urine) showed moderate to high
correlations, with the strongest associations observed for F2-
IsoP and IsoF. For example, Spearman correlation coefﬁcients
at the end of cardiac surgery were between 0.43 and 0.72
among urine oxidative stress biomarkers (P<0.001 for each);
conversely, plasma concentrations of each biomarker corre-
lated either not at all or only weakly with their respective urine
levels. For example, plasma and urine isofurans did not
correlate signiﬁcantly at any of the time points assessed (r =
0.05 to 0.05, P≥0.32 for each).
There were signiﬁcant changes in the concentrations of
oxidative stress biomarkers aftert cardiac surgery, with
distinct patterns for plasma and urine measurements, as well
as for subjects who did or did not develop PoAF (Figures 1
and 2). One of the most pronounced change was the 2- to 3-
fold increase over baseline in urine level of all 3 oxidative
stress biomarkers following cardiac surgery (P<0.001 for
each). Furthermore, at the end of surgery, F2-isoP and IsoF
levels were 20% and 50% higher in subjects who
subsequently developed PoAF (P≤0.009, adjusted for enroll-
ment biomarker concentrations). At postoperative day 2, urine
levels of all 3 biomarkers fell signiﬁcantly (paired t test
relative to end of surgery, P≤0.03 for each), to concentrations
comparable to baseline. Plasma levels of oxidative stress
biomarkers did not show such marked variation as urine
concentrations throughout the study. At postoperative day 2,
levels of F2-IsoP and IsoF were slightly lower relative to the
end of surgery (10%, P≤0.04 for each), and F2-IsoP levels
were 20% higher in subjects who developed PoAF than in
those who did not (P=0.05). Plasma F3-Iso was higher at the
end of cardiac surgery (40%, P<0.001) and remained similar
at postoperative day 2.
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Among the 551 subjects in the study, 171 developed PoAF
during follow-up. Oxidative stress biomarkers in plasma or
urine at baseline did not associate signiﬁcantly with PoAF
(online supplemental data, Tables S2 and S3). By the end of
surgery, however, the concentrations of IsoF in urine and
plasma associated with elevated risk of PoAF. For example,
the OR (95% CI) for participants in the highest compared with
the lowest quartile of urine IsoF was 1.95 (1.05 to 3.62, P for
trend=0.01). Urine, but not plasma F3-IsoP, concentration also
associated with higher PoAF risk, with extreme quartile OR
(95% CI) of 2.10 (1.04 to 2.25, P for trend=0.04). F2-IsoP at
the end of surgery did not associate with PoAF. At
postoperative day 2, plasma F2-IsoP and IsoF both associated
with higher PoAF risk, with extreme quartile OR (95% CI) of
2.53 (1.14 to 5.58) and 2.98 (1.22 to 7.25), respectively.
Urine concentrations of these biomarkers did not signiﬁcantly
Table. Baseline Characteristics of Subjects With Oxidative
Stress Biomarker Measures in the OPERA Trial (N=551)
Characteristics Summary Statistics*
Country, %
USA 57.0
Italy 32.1
Argentina 10.9
Age, y 62.712.7
Sex, % male 72.2
Planned valve surgery, % 55.0
Planned CABG, % 48.3
Current smoking, % 13.3
Diabetes mellitus, % 29.8
Body mass index, kg/m2 29.06.1
Hypertension, % 77.1
COPD, % 14.3
Dyslipidemia, % 64.1
Chronic renal failure, % 6.5
Coronary heart disease, % 44.5
Prior myocardial infarction, % 22.9
Prior PCI, % 14.5
Prior arrhythmias, % 13.8
Prior atrial fibrillation, % 8.0
Congestive heart failure, % 20.0
Ejection fraction, % 56.211.2
b-Blocker, % 54.1
Statins, % 56.6
ACE inhibitor, % 35.6
Aspirin, % 61.9
Antiarrhythmics, % 4.4
Logistic Euroscore, units 6.27.5
CABG indicates coronary artery bypass graft surgery; COPD, chronic obstructive
pulmonary disease; PCI, percutaneous coronary intervention; ACE, angiotensin-
converting enzyme.
*Values are meanSD for continuous variables, and percent for categorical variables.
Figure 1. Plasma oxidative stress biomarkers concentration
(pg/mL) at baseline (recruitment), end of surgery (at time of
closure), and postoperative day 2. Data shown are meanSE. The
white and gray bars represent subjects without and with incident
postoperative atrial ﬁbrillation (PoAF), respectively. *Mean plasma
level of F2-isoprostanes were 20% higher in patients who
developed PoAF than in those who did not (P=0.05, adjusted for
end of surgery F2-isoprostane concentrations).
Figure 2. Urine creatinine-adjusted concentration of oxidative
stress biomarkers (ng/mg) at baseline (recruitment), end of
surgery (at time of closure), and postoperative day 2. Data shown
are meanSE. The white and gray bars represent subjects
without and with incident postoperative atrial ﬁbrillation (PoAF),
respectively. *Mean urine F2-isoprostane and isofuran levels were
20% and 50% higher in subjects who subsequently developed
PoAF (P≤0.009, adjusted for baseline concentrations).
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associate with PoAF. Similarly, levels of F3-IsoP at postop-
erative day 2 in urine and plasma were not associated with
subsequent PoAF. Semiparametric analyses with restricted
cubic splines suggested relatively linear (monotonic) asso-
ciations of oxidative stress biomarkers at the end of
surgery and postoperative day 2 with incident PoAF
(Figures 3 and 4).
Results were similar when the biomarkers were assessed
continuously. For example, each doubling of urine IsoF at the
end of surgery was associated with an OR (95% CI) of 1.20
(1.03 to 1.41, P=0.02). In sensitivity analyses, changes in
plasma and urine oxidative stress biomarker concentration
from baseline to the end of surgery showed similar direction
and magnitude of association with PoAF as end of surgery
levels alone (not shown). Further adjustment for study
treatment, valve surgery, time on pump, prevalent obstructive
pulmonary disease, antiarrhythmic medication, changes in
white blood cell count, and aspirin use did not appreciably
alter the results (not shown). There was little evidence that
country, age, sex, body mass index, type of surgery, smoking,
A
B C
Figure 3. Multivariable-adjusted association of plasma (A) isofuran at end of surgery (B) isofuran at postoperative day 2 and (C)
F2-isoprostanes at postoperative day 2 with postoperative atrial ﬁbrillation (PoAF), evaluated by restricted cubic splines and logistic regression.
Biomarkers underwent log-transformation before analyses as they were right-skewed, and analyses adjusted for age (years), sex (male/female),
country (US, Italy, Argentina), body mass index (kg/m2), prevalent hypertension (yes/no), prevalent diabetes (yes/no), prevalent coronary heart
disease (yes/no), prevalent chronic renal failure (yes/no), prevalent heart failure (yes/no), smoking (never or former/current), dyslipidemia
(yes/no), statin medication use (yes/no), ejection fraction (%), and logistic Euroscore (continuous). The solid red line and shaded areas
represent the OR and 95% CIs, respectively, in comparison to the reference level representing the median value of the lowest quartile (12.5th
percentile). Dotted vertical lines correspond to the 10th, 25th, 50th, 75th, and 90th percentiles of the log biomarker concentrations. There was
overall linear association for each biomarkers with PoAF (P≤0.02) but little evidence of nonlinearity (P≥0.83).
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and aspirin and statin use signiﬁcantly modiﬁed the
association of oxidative stress biomarkers and PoAF (Bonfer-
roni corrected, P for interaction ≥0.29 for each).
Discussion
In this prospective cohort study of cardiac surgery patients,
higher end of surgery and postoperative oxidative stress
assessed by F2-IsoP, IsoF, and F3-IsoP associated
independently with elevated risk of PoAF. The magnitude of
associations was substantial, and subjects in the top quartile
of lipid peroxidation biomarker had up to 3-fold higher odds of
PoAF. In contrast, baseline IsoP and IsoF did not associate
with PoAF.
Accumulating experimental evidence supports the biologic
plausibility of these ﬁndings by indicating a causal role of
oxidative stress in pathologic atrial structural remodeling,
abnormal ion channel function, and increased vulnerability to
AF.21 In animals, risk factors for AF development, such as
hypertension and heart failure, link with increased ROS
production,22,23 and treatment with antioxidants reduces
atrial ﬁbrosis and prevents tissue oxidative damage and
occurrence of AF.24–26 Arachidonic acid and eicosapentaenoic
acids in cardiac membranes may also inﬂuence AF develop-
ment.27 Structural modiﬁcation of these polyunsaturated fatty
acids by ROS to IsoP and IsoF may disrupt their capacity to
regulate protein and ion channel functions.28 Furthermore,
not only do IsoP and IsoF serve as sensitive biomarkers of
oxidative stress in vivo; they also may contribute to inﬂam-
mation, such as by enhancing adhesion of monocytes to
endothelial cells.29,30
The observed increase in urine F2-IsoP, IsoF, and F3-IsoP
between baseline and the end of surgery is consistent with
cardiac surgery–induced oxidative stress.31 Our data also
indicate the transience of the imbalance in ROS generation
and antioxidant defense triggered by cardiac surgery, as levels
of urine biomarkers fell to near baseline levels by postoper-
ative day 2. Whereas urine levels of these oxidative stress
biomarkers provide a time-integrated measure of subacute
systemic oxidative stress, their plasma levels reﬂect acute
systemic oxidative stress, due to their rapid metabolism and
renal excretion,32 which may explain the relative stability of
plasma levels of these biomarkers observed in our study.
Urine IsoF demonstrated a relatively greater increase than
IsoP. Although both IsoF and IsoP arise from ROS-mediated
peroxidation of polyunsaturated fatty acids, mitochondrial
dysfunction and elevated oxygen concentration favor forma-
tion of IsoF.16 Our results, therefore, highlight the likely
importance of identifying not only endogenous sources of
oxidative stress but also factors that expose patients to
increased oxygen concentration, such as inspired oxygen
supplementation during cardiac surgery.
Our investigation demonstrates that higher oxidative stress
at postoperative day 2 associates with subsequent risk of
PoAF. These ﬁndings highlight the need to identify therapies
that could reduce oxidative stress throughout the perioper-
ative time course, speciﬁcally targeting oxidants that may
cause lipid oxidation. Increasing evidence suggest both
statins, which downregulate NADPH oxidase,33 and antioxi-
dant scavengers are of potential interest, and recent meta-
analyses of controlled trials found supplementation with
A
B
Figure 4. Multivariable-adjusted association of end of surgery
(A) urine isofurans and (B) urine F3-isoprostanes with postoper-
ative atrial ﬁbrillation (PoAF), evaluated by restricted cubic splines
and logistic regression. Biomarkers underwent log-transformation
before analyses as they were right-skewed, and analyses adjusted
for age (years), sex (male/female), country (US, Italy, Argentina),
body mass index (kg/m2), prevalent hypertension (yes/no),
prevalent diabetes (yes/no), prevalent coronary heart disease
(yes/no), prevalent chronic renal failure (yes/no), prevalent heart
failure (yes/no), smoking (never or former/current), dyslipidemia
(yes/no), statin medication use (yes/no), ejection fraction (%),
and logistic Euroscore (continuous). The solid red line and shaded
areas represent the OR and 95% CIs, respectively, in comparison
to the reference level representing the median value of the lowest
quartile (12.5th percentile). Dotted vertical lines correspond to
the 10th, 25th, 50th, 75th, and 90th percentiles of the log
biomarker concentrations. Both biomarkers associated linearly
overall with PoAF (P=0.02 for each) but showed little evidence of
nonlinearity (P≥0.26 for each).
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statins or putative antioxidants (eg, vitamin C) reduced the
risk of PoAF.34,35 However, these ﬁndings should be inter-
preted with caution given the large heterogeneity observed
between the results of individual trials and the lack of
evidence that the treatments actually reduced oxidative stress
in vivo.35 Our ﬁndings indicate that future trials could
rationally determine the dose and duration of statin or
antioxidant therapy for PoAF prevention, based on their ability
to reduce plasma or urine IsoP and IsoF. Because oxidative
stress may activate inﬂammation, future studies should also
examine inﬂammatory biomarkers (eg, myeloperoxidase),
which could provide additional information.6,36
Our study has important strengths. The use of highly
sensitive and speciﬁc IsoP and IsoF, assessed across
multiple perioperative time points allowed comprehensive
evaluation of the relationships of lipid oxidation and PoAF,
and inclusion of these complementary biomarkers provide
additional insight into potential oxidative stress mechanisms.
The study used highly accurate and reproducible assays to
measure the biomarkers, limiting the likelihood of misclas-
siﬁcation of these exposures. The prospective design min-
imized selection bias and enabled inference on temporality
of associations. Careful collection of information on many
potential covariates allowed detailed adjustment to control
for confounding. A centralized events committee conducted
careful adjudication of PoAF events that lowered the
possibility of outcome misclassiﬁcation. Subjects in the
OPERA trial were from different countries with varied
demographic and lifestyle characteristics, which enhances
generalizability.
Potential limitations also merit consideration. While IsoP
and IsoF quantify the extent of lipid peroxidation, they do not
provide insight into oxidative damage to other cellular
compartments such as proteins and DNA, and these should
be assessed in the future by using other validated biomarkers.
We adjusted for a range of important demographic and clinical
risk factors, but we cannot exclude the possibility of residual
confounding due to unmeasured or imprecisely measured
factors. Only a subset of OPERA trial subjects participated in
this biologic study, which reduced statistical power. Never-
theless, this current investigation represents by far the largest
study assessing objective, validated oxidative stress biomar-
kers in cardiac surgery patients. Although results from this
study are relevant to cardiac surgery patients, ﬁndings may
not be applicable to other populations at risk of AF. Of course,
the strong association demonstrated by these data cannot
establish causality between oxidative stress and the advent of
PoAF. Yet, the grounds for biological plausibility mentioned
here do support a causal link between oxidative stress and
PoAF. Finally, our ﬁndings suggest the need to carefully
evaluate the effect of ﬁsh oil treatment on oxidative stress
levels in future studies.
In summary, cardiac surgery induce acute increase in
oxidative stress as assessed with urine levels of IsoP and IsoF.
In addition, elevated end of surgery and postoperative levels
of these oxidative stress biomarkers relate to higher risk of
PoAF. These novel results adds to growing evidence support-
ing the likely key pathogenic role of elevated oxidative stress
in PoAF and suggest that further development of therapies
targeting oxidative stress pathways for the prevention of PoAF
is warranted.
Sources of Funding
This work was supported by the National Heart, Lung, and
Blood Institute, National Institutes of Health (1 RC2
HL101816, and R01HL085710); GlaxoSmithKline; Sigma
Tau; and Pronova BioPharma. The funding organizations had
no role in the design, conduct, or analysis of the OPERA trial
or this biologic substudy. The authors thank all OPERA
participants.
Disclosures
Dr Mozaffarian reports ad hoc travel reimbursement or
honoraria from Bunge, Pollock Institute, Quaker Oats, and Life
Sciences Research Organization; ad hoc consulting fees from
McKinsey Health Systems Institute, Foodminds, Nutrition
Impact, Amarin, Omthera, and Winston and Strawn LLP;
membership, Unilever North America Scientiﬁc Advisory Board;
royalties fromUpToDate; and research grants from the National
Institutes of Health. The other authors report no conﬂicts.
References
1. Mitchell LB. Canadian cardiovascular society atrial ﬁbrillation guidelines 2010:
prevention and treatment of atrial ﬁbrillation following cardiac surgery. Can J
Cardiol. 2011;27:91–97.
2. Maesen B, Nijs J, Maessen J, Allessie M, Schotten U. Post-operative atrial
ﬁbrillation: a maze of mechanisms. Europace. 2012;14:159–174.
3. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian
A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, Van Wagoner DR. Ascorbate
attenuates atrial pacing-induced peroxynitrite formation and electrical remod-
eling and decreases the incidence of postoperative atrial ﬁbrillation. Circ Res.
2001;89:E32–E38.
4. Nishijima Y, Sridhar A, Bonilla I, Velayutham M, Khan M, Terentyeva R, Li C,
Kuppusamy P, Elton TS, Terentyev D, Gyorke S, Zweier JL, Cardounel AJ,
Carnes CA. Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to
heart failure-induced alterations in atrial electrophysiology. Cardiovasc Res.
2011;91:71–79.
5. Lenaerts I, Driesen RB, Hermida N, Holemans P, Heidbuchel H, Janssens S,
Balligand JL, Sipido KR, Willems R. Role of nitric oxide and oxidative stress in a
sheep model of persistent atrial ﬁbrillation. Europace. 2013;15:754–760.
6. Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inﬂammation and
oxidative stress in atrial ﬁbrillation: role of 3-hydroxy-3-methylglutaryl-
coenzyme a reductase inhibition with statins. Antioxid Redox Signal.
2014;20:1268–1285.
7. Granger DN, Vowinkel T, Petnehazy T. Modulation of the inﬂammatory
response in cardiovascular disease. Hypertension. 2004;43:924–931.
8. Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonop-
oulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, Bakogiannis C, Sayeed R,
Triantafyllou C, Koumallos N, Psarros C, Miliou A, Stefanadis C, Channon KM,
DOI: 10.1161/JAHA.115.001886 Journal of the American Heart Association 7
Oxidative Stress and Postoperative AF Wu et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Casadei B. Myocardial redox state predicts in-hospital clinical outcome after
cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll
Cardiol. 2012;59:60–70.
9. Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B.
Association of atrial nicotinamide adenine dinucleotide phosphate oxidase
activity with the development of atrial ﬁbrillation after cardiac surgery. J Am
Coll Cardiol. 2008;51:68–74.
10. Girerd N, Pibarot P, Fournier D, Daleau P, Voisine P, O’Hara G, Despres JP,
Mathieu P. Middle-aged men with increased waist circumference and elevated
C-reactive protein level are at higher risk for postoperative atrial ﬁbrillation
following coronary artery bypass grafting surgery. Eur Heart J. 2009;30:1270–
1278.
11. Ramlawi B, Otu H, Mieno S, Boodhwani M, Sodha NR, Clements RT, Bianchi
C, Sellke FW. Oxidative stress and atrial ﬁbrillation after cardiac surgery: a
case-control study. Ann Thorac Surg. 2007;84:1166–1172; discussion 1172-
1163.
12. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, Nyska
A, Wachsman JT, Ames BN, Basu S, Brot N, Fitzgerald GA, Floyd RA, George M,
Heinecke JW, Hatch GE, Hensley K, Lawson JA, Marnett LJ, Morrow JD, Murray
DM, Plastaras J, Roberts LJ II, Rokach J, Shigenaga MK, Sohal RS, Sun J, Tice
RR, Van Thiel DH, Wellner D, Walter PB, Tomer KB, Mason RP, Barrett JC.
Biomarkers of oxidative stress study II: are oxidation products of lipids,
proteins, and DNA markers of CCL4 poisoning? Free Radic Biol Med.
2005;38:698–710.
13. Ulus AT, Aksoyek A, Ozkan M, Katircioglu SF, Basu S. Cardiopulmonary bypass
as a cause of free radical-induced oxidative stress and enhanced blood-borne
isoprostanes in humans. Free Radic Biol Med. 2003;34:911–917.
14. Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ,
Latini R, Libby P, Lombardi F, O’Gara PT, Page RL, Tavazzi L, Tognoni G. Fish oil
and postoperative atrial ﬁbrillation: the omega-3 fatty acids for prevention of
post-operative atrial ﬁbrillation (OPERA) randomized trial. JAMA.
2012;308:2001–2011.
15. Roberts LJ II, Milne GL. Isoprostanes. J Lipid Res. 2009;50(suppl):S219–S223.
16. Fessel JP, Jackson Roberts L. Isofurans: novel products of lipid peroxidation
that deﬁne the occurrence of oxidant injury in settings of elevated oxygen
tension. Antioxid Redox Signal. 2005;7:202–209.
17. Mozaffarian D, Marchioli R, Gardner T, Ferrazzi P, O’Gara P, Latini R, Libby P,
Lombardi F, Macchia A, Page R, Santini M, Tavazzi L, Tognoni G. The omega-3
fatty acids for prevention of post-operative atrial ﬁbrillation trial—rationale
and design. Am Heart J. 2011;162:56–63.e53.
18. Wu JH, Marchioli R, Silletta MG, Macchia A, Song X, Siscovick DS, Harris WS,
Masson S, Latini R, Albert C, Brown NJ, Lamarra M, Favaloro RR, Mozaffarian
D. Plasma phospholipid omega-3 fatty acids and incidence of postoperative
atrial ﬁbrillation in the OPERA trial. J Am Heart Assoc. 2013;2:e000397 doi:
10.1161/JAHA.113.000397.
19. Milne GL, Gao B, Terry ES, Zackert WE, Sanchez SC. Measurement of F2-
isoprostanes and isofurans using gas chromatography-mass spectrometry.
Free Radic Biol Med. 2013;59:36–44.
20. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur
Heart J. 2003;24:881–882.
21. Sovari AA, Dudley SC. Antioxidant therapy for atrial ﬁbrillation: lost in
translation? Heart. 2012;98:1615–1616.
22. Briones AM, Touyz RM. Oxidative stress and hypertension: current concepts.
Curr Hypertens Rep. 2010;12:135–142.
23. Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just damage.
Eur Heart J. 2003;24:2161–2163.
24. Li Y, Sheng L, Li W, Liu W, Gong Y, Xue H, Shan H. Probucol attenuates atrial
structural remodeling in prolonged pacing-induced atrial ﬁbrillation in dogs.
Biochem Biophys Res Commun. 2009;381:198–203.
25. Fukunaga N, Takahashi N, Hagiwara S, Kume O, Fukui A, Teshima Y, Shinohara
T, Nawata T, Hara M, Noguchi T, Saikawa T. Establishment of a model of atrial
ﬁbrillation associated with chronic kidney disease in rats and the role of
oxidative stress. Heart Rhythm. 2012;9:2023–2031.
26. Youn JY, Zhang J, Zhang Y, Chen H, Liu D, Ping P, Weiss JN, Cai H. Oxidative
stress in atrial ﬁbrillation: an emerging role of NADPH oxidase. J Mol Cell
Cardiol. 2013;62:72–79.
27. Wu JH, Lemaitre RN, King IB, Song X, Sacks FM, Rimm EB, Heckbert SR,
Siscovick DS, Mozaffarian D. Association of plasma phospholipid long-chain
omega-3 fatty acids with incident atrial ﬁbrillation in older adults: the
Cardiovascular Health Study. Circulation. 2012;125:1084–1093.
28. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects
on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol.
2011;58:2047–2067.
29. Leitinger N, Huber J, Rizza C, Mechtcheriakova D, Bochkov V, Koshelnick Y,
Berliner JA, Binder BR. The isoprostane 8-iso-PGF(2alpha) stimulates endo-
thelial cells to bind monocytes: differences from thromboxane-mediated
endothelial activation. FASEB J. 2001;15:1254–1256.
30. Huber J, Bochkov VN, Binder BR, Leitinger N. The isoprostane 8-iso-PGE2
stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP
kinase-dependent signaling pathways. Antioxid Redox Signal. 2003;5:163–169.
31. Chambers DJ. Oxidative stress injury during cardiac surgery: how important is
it? Cardiovasc Res. 2007;73:626–628.
32. Basu S. Metabolism of 8-iso-prostaglandin F2alpha. FEBS Lett. 1998;428:32–
36.
33. Violi F, Calvieri C, Ferro D, Pignatelli P. Statins as antithrombotic drugs.
Circulation. 2013;127:251–257.
34. Kuhn EW, Liakopoulos OJ, Stange S, Deppe AC, Slottosch I, Choi YH, Wahlers
T. Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000
patients. Eur J Cardiothorac Surg. 2014;45:17–26; discussion 26.
35. Violi F, Pastori D, Pignatelli P, Loffredo L. Antioxidants for prevention of atrial
ﬁbrillation: a potentially useful future therapeutic approach? A review of the
literature and meta-analysis. Europace. 2014;16:1107–1116.
36. Gill R, Tsung A, Billiar T. Linking oxidative stress to inﬂammation: toll-like
receptors. Free Radic Biol Med. 2010;48:1121–1132.
DOI: 10.1161/JAHA.115.001886 Journal of the American Heart Association 8
Oxidative Stress and Postoperative AF Wu et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
